2024
Drug-Induced Thrombocytopenia: A Critical Condition in Hospitalized Cancer Patients
Abouelkheer Y, Ranat R, Phuong L, Boxer D, Ahasic A. Drug-Induced Thrombocytopenia: A Critical Condition in Hospitalized Cancer Patients. Blood 2024, 144: 5544-5544. DOI: 10.1182/blood-2024-211937.Peer-Reviewed Original ResearchDrug-induced thrombocytopeniaHigh risk of bleedingPlatelet factor 4Risk of bleedingPlatelet countPostoperative dayIntravenous immunoglobulinSurgical cancer patientsCancer patientsSevere thrombocytopeniaCase of severe thrombocytopeniaRecovery of platelet countsHigh riskEtiology of thrombocytopeniaBone marrow suppressionClear-cell carcinomaHeparin-Induced ThrombocytopeniaDisseminated intravascular coagulopathyImmune-mediated conditionsPostoperative day 3Postoperative day 7Consumption of plateletsPlanned surgical resectionPlatelet factor 4 antigenAdministration of dexamethasoneClinical outcomes in critically ill children on extracorporeal membrane oxygenation with severe thrombocytopenia
Labarinas S, Norbisrath K, Johnson D, Meliones J, Greenleaf C, Salazar J, Karam O. Clinical outcomes in critically ill children on extracorporeal membrane oxygenation with severe thrombocytopenia. Perfusion 2024, 40: 590-598. PMID: 38626382, DOI: 10.1177/02676591241247981.Peer-Reviewed Original ResearchExtracorporeal membrane oxygenationExtracorporeal membrane oxygenation daysCritically Ill ChildrenSevere thrombocytopeniaPlatelet countPlatelet transfusionsMembrane oxygenationIll childrenMortality rateDuration of extracorporeal membrane oxygenationAssociated with in-hospital mortality ratesExtracorporeal membrane oxygenation durationSingle-center retrospective studyPlatelet transfusion strategyFrequent platelet transfusionsIn-hospital mortality rateAssociated with bleedingTransfusion strategyAssociated with higher proportionsMedian weightMulticenter studyRetrospective studyClinical outcomesOn-ECMOThrombocytopeniaTreatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis
Sirotich E, Nazaryan H, Chowdhury S, Guyatt G, Agarwal A, Leong R, Wen A, Xu E, Liu B, Pallapothu S, Rathod P, Kwon H, Dookie J, Shafiee A, Charness J, DiRaimo J, Paynter D, Pruitt B, Strachan G, Couban R, Ye Z, Arnold D. Treatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis. Systematic Reviews 2024, 13: 21. PMID: 38184622, PMCID: PMC10770981, DOI: 10.1186/s13643-023-02436-6.Peer-Reviewed Original ResearchConceptsCritical bleedingSystematic reviewEvidence-based treatment protocolsBleeding-related mortalityCochrane Central RegisterEvidence-based recommendationsFull-text screeningBleeding eventsImmune thrombocytopeniaRecommendations AssessmentCentral RegisterControlled TrialsPrimary outcomeSevere thrombocytopeniaPlatelet countEligible studiesPatient outcomesEmergency settingOvid MEDLINEObservational studyTreatment protocolHigh riskMedical emergencyElectronic databasesMethodsLiterature search
2023
105: Clinical Outcomes in Critically Ill Children on Extracorporeal Membrane Oxygenation with Severe Thrombocytopenia.
Labarinas S, Singh K, Meliones J, Johnson D, Greenleaf C, Salazar J, Karam O. 105: Clinical Outcomes in Critically Ill Children on Extracorporeal Membrane Oxygenation with Severe Thrombocytopenia. ASAIO Journal 2023, 69: 57-57. DOI: 10.1097/01.mat.0000990932.67126.dc.Peer-Reviewed Original ResearchThrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings — Connecticut, July 2022
Hogeland E, Somers T, Yip L, Doyon S, Redlich C, Orsey A, Woda C, Swan S, Feder H. Thrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings — Connecticut, July 2022. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1027-1031. PMID: 37733629, PMCID: PMC10519713, DOI: 10.15585/mmwr.mm7238a2.Peer-Reviewed Original ResearchConceptsIntravenous immune globulinSevere thrombocytopeniaElemental mercury poisoningImmune thrombocytopenic purpuraThrombopoietin receptor agonistsPossible infectious causesElemental mercury toxicityPublic health outreachPetechial rashOral mucositisImmune globulinProlonged hospitalizationInfectious causesPlatelet transfusionsThrombocytopenic purpuraThrombocytopenia AssociatedReceptor agonistHealth outreachPoison controlEarly detectionToxic exposureMercury exposureEnvironmental exposuresMercury poisoningDimercaptosuccinic acidEgyptian Gaucher disease type 3 patients: a large cohort study spanning two decades
El-Beshlawy A, Abdel-Azim K, Abdel-Salam A, Selim Y, Said F, Gebril N, Fateen E, Mistry P. Egyptian Gaucher disease type 3 patients: a large cohort study spanning two decades. Journal Of Rare Diseases 2023, 2: 7. DOI: 10.1007/s44162-023-00011-0.Peer-Reviewed Original ResearchGD type 3Enzyme replacement therapyYears of ERTLarge single-center studySingle-center studyThird of patientsOverall survival ratePediatric hematology clinicLong-term outcomesLarge cohort studyBulbar symptomsGD3 patientsHepatopulmonary syndromeCohort studyEgyptian patientsLiver cirrhosisHematology clinicNeurological assessmentSevere thrombocytopeniaReplacement therapySevere splenomegalyFamily historyGenotype/phenotype studiesSevere hepatomegalyPatientsSpleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Derkach A, Rampal R, Buckley S, Roman-Torres K. Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis. Journal Of Clinical Oncology 2023, 41: 7018-7018. DOI: 10.1200/jco.2023.41.16_suppl.7018.Peer-Reviewed Original ResearchSpleen volume reductionOverall survivalMF patientsNon-respondersOS benefitOS analysisSpleen volumePERSIST-2Median relative dose intensityAssociated with improved OSAssociated with improved survivalReduced spleen volumeAssociated with significant OS benefitRelative dose intensitySignificant OS benefitTreated with ruxolitinibLog-rank testUnique survival advantagesDose intensityProgressive cytopeniasMarrow fibrosisOS curvesSevere thrombocytopeniaPlatelet countSpleen reduction
2021
Epidemiology of Bleeding in Critically Ill Children With an Underlying Oncologic Diagnosis
Romano J, Martinez M, Levasseur J, Killinger JS, Karam O, Nellis ME. Epidemiology of Bleeding in Critically Ill Children With an Underlying Oncologic Diagnosis. Critical Care Explorations 2021, 3: e0572. PMID: 34746797, PMCID: PMC8565795, DOI: 10.1097/cce.0000000000000572.Peer-Reviewed Original ResearchSevere bleedingOncologic diagnosisIll childrenEpidemiology of BleedingPICU-free daysSevere bleeding eventsVentilator-free daysIll pediatric patientsMedian platelet countRetrospective cohort studyInternational normalized ratioBlood component therapyVulnerable patient populationComprehensive cancer centerBleeding eventsHemostatic medicationsPICU admissionPercent patientsTransplant statusCohort studyMedian agePediatric patientsExact epidemiologySevere thrombocytopeniaPlatelet countDefinition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology
Sirotich E, Guyatt G, Gabe C, Ye Z, Beck C, Breakey V, Cooper N, Cuker A, Charness J, de Wit K, DiRaimo J, Fein S, Grace R, Hassan Z, Jamula E, Kang M, Manski C, O'Connor C, Pai M, Paynter D, Porter S, Pruitt B, Strachan G, Webert K, Yan J, Kelton J, Bakchoul T, Arnold D. Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal Of Thrombosis And Haemostasis 2021, 19: 2082-2088. PMID: 34327824, DOI: 10.1111/jth.15368.Peer-Reviewed Original ResearchConceptsImmune thrombocytopeniaSevere thrombocytopeniaGuideline panelCritical anatomical sitesLow platelet countISTH SSC SubcommitteeBleeding eventsMajor bleedsOngoing bleedPlatelet immunologyCompartment syndromeHemodynamic instabilityRespiratory compromisePhysiologic riskPlatelet countAutoimmune diseasesUrgent treatmentPatient representativesAnatomical sitesThrombocytopeniaUpcoming guidelinesPatientsBleedStandardized definitionsClinical expertsEffect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit
Mazloomzadeh S, Khaleghparast S, Ghadrdoost B, Mousavizadeh M, Baay M, Noohi F, Sharifnia H, Ahmadi A, Tavan S, Malekpour Alamdari N, Fathi M, Soleimanzadeh M, Mostafa M, Davoody N, Zarinsadaf M, Tayyebi S, Farrokhzadeh F, Nezamabadi F, Soomari E, Sadeghipour P, Talasaz A, Rashidi F, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M, Sezavar S, Payandemehr P, Dabbagh A, Moghadam K, Jamalkhani S, Khalili H, Yadollahzadeh M, Riahi T, Rezaeifar P, Tahamtan O, Matin S, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian S, Shahmirzaei S, Bakhshandeh H, Amin A, Rafiee F, Baghizadeh E, Mohebbi B, Parhizgar S, Aliannejad R, Eslami V, Kashefizadeh A, Kakavand H, Hosseini S, Shafaghi S, Ghazi S, Najafi A, Jimenez D, Gupta A, Madhavan M, Sethi S, Parikh S, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane A, Van Tassell B, Dobesh P, Stone G, Lip G, Krumholz H, Goldhaber S, Bikdeli B. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA 2021, 325: 1620-1630. PMID: 33734299, PMCID: PMC7974835, DOI: 10.1001/jama.2021.4152.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsCOVID-19Drug Administration ScheduleEnoxaparinExtracorporeal Membrane OxygenationFemaleHemorrhageHospitalizationHumansIntensive Care UnitsIranLength of StayMaleMiddle AgedOdds RatioOutcome Assessment, Health CareOxygen Inhalation TherapyPulmonary EmbolismThrombocytopeniaThrombosisTreatment OutcomeVenous ThrombosisConceptsStandard-dose prophylactic anticoagulationIntensive care unitIntermediate-dose groupProphylactic anticoagulationPrimary efficacy outcomeExtracorporeal membrane oxygenationIntermediate doseMajor bleedingProphylaxis groupEfficacy outcomesMembrane oxygenationPrimary outcomeThrombotic eventsArterial thrombosisCare unitSevere thrombocytopeniaCOVID-19Bleeding Academic Research ConsortiumExtracorporeal membrane oxygenation treatmentPrespecified safety outcomesRoutine empirical useStandard prophylactic anticoagulationAcademic Research ConsortiumMembrane oxygenation treatmentAntithrombotic prophylaxis
2020
Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia
Patel PA, Chandrakasan S, Mickells GE, Yildirim I, Kao CM, Bennett CM. Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia. 2020, 146: e20201437. PMID: 32366611, PMCID: PMC7329259, DOI: 10.1542/peds.2020-1437.Peer-Reviewed Original ResearchConceptsSevere acute respiratory distress syndromeSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Coronavirus disease 2019Respiratory failureSevere thrombocytopeniaCoronavirus 2Disease 2019Pediatric coronavirus disease 2019Airway pressure release ventilationAcute respiratory distress syndromeBroad antiviral agentPediatric COVID-19Respiratory distress syndromeUnderlying medical conditionsPast medical historySignificant clinical benefitIntravenous immunoglobulinElevated markersClinical courseDistress syndromePrompt improvementSevere morbidityManagement of major bleeds in patients with immune thrombocytopenia
Mithoowani S, Cervi A, Shah N, Ejaz R, Sirotich E, Barty R, Li N, Nazy I, Arnold D. Management of major bleeds in patients with immune thrombocytopenia. Journal Of Thrombosis And Haemostasis 2020, 18: 1783-1790. PMID: 32219982, DOI: 10.1111/jth.14809.Peer-Reviewed Original ResearchConceptsMajor bleedsImmune thrombocytopeniaEmergency departmentITP patientsEvidence-based treatment strategiesIntravenous immune globulinRetrospective cohort studyPermanent neurological disabilityITP therapyMajor bleedingRecurrent bleedsHemodynamic instabilityMinor bleedingCohort studyED visitsGross hematuriaImmune globulinAcute treatmentNeurological disabilityArterial thrombosisPlatelet transfusionsSevere thrombocytopeniaSignificant morbidityMale sexRisk factors
2018
Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia
Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Prabhu-Coelho N, Larson MV, Wong Kee Song LM, Rajan E. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointestinal Endoscopy 2018, 88: 55-61. PMID: 29408558, DOI: 10.1016/j.gie.2018.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCause of DeathCohort StudiesComorbidityEndoscopy, GastrointestinalErythrocyte TransfusionFemaleGastrointestinal HemorrhageHematemesisHemostasis, SurgicalHumansHypotensionIntensive Care UnitsInternational Normalized RatioLiver CirrhosisLung DiseasesMaleMelenaMiddle AgedMortalityPartial Thromboplastin TimePlatelet TransfusionRecurrenceRetrospective StudiesRisk FactorsSeverity of Illness IndexThrombocytopeniaYoung AdultConceptsIncreased international normalized ratioOvert gastrointestinal bleedingInitial hemostasis rateRecurrent bleeding rateGastrointestinal bleedingLiver cirrhosisSevere thrombocytopeniaPlatelet transfusionsPlatelet countTherapeutic yieldRecurrent bleedingHemostasis rateAdverse eventsBleeding rateHigh initial hemostasis rateIntensive care unit admissionCare unit admissionPredictors of mortalityCause mortality ratesMedian platelet countHours of presentationInternational normalized ratioSetting of thrombocytopeniaProcedural adverse eventsPartial thromboplastin time
2017
Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction
Feher A, Kampaktsis PN, Parameswaran R, Stein EM, Steingart R, Gupta D. Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction. The Oncologist 2017, 22: 213-221. PMID: 28159866, PMCID: PMC5330698, DOI: 10.1634/theoncologist.2016-0110.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombocytopenic cancer patientsSevere thrombocytopeniaMajor bleedingHematologic malignanciesImproved survivalMyocardial infarctionAspirin useCancer patientsPatient cohortDays of AMIGuideline-recommended medical therapyMemorial Sloan-Kettering Cancer CenterHigh-risk patient cohortTreatment of AMIBenefits of aspirinFatal bleeding eventsOverall patient cohortAspirin therapyBleeding eventsSTP patientsThienopyridine treatmentMedical therapyPlatelet countCancer Center
2014
Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non–ST-segment elevation acute coronary syndrome
Vora A, Chenier M, Schulte P, Goodman S, Peterson E, Pieper K, Jolicoeur M, Mahaffey K, White H, Wang T. Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non–ST-segment elevation acute coronary syndrome. American Heart Journal 2014, 168: 189-196.e1. PMID: 25066558, DOI: 10.1016/j.ahj.2014.04.010.Peer-Reviewed Original ResearchConceptsDischarge medication useSevere thrombocytopeniaMild thrombocytopeniaAntiplatelet therapyCoronary syndromeNadir platelet count <Associated with increased in-hospital mortalityNon-ST-segment elevation acute coronary syndromeElevation acute coronary syndromeOne-year mortality ratePlatelet count <Associated with increased mortalityNadir platelet countLong-term mortalityLong-term outcomesMedication useAcute coronary syndromeIn-Hospital MortalityThrombocytopenia severityBleeding riskHemorrhagic complicationsPlatelet countAcquired thrombocytopeniaSYNERGY trialThrombocytopeniaRegional Differences of Leptospirosis in Sri Lanka: Observations from a Flood-Associated Outbreak in 2011
Agampodi SB, Dahanayaka NJ, Bandaranayaka AK, Perera M, Priyankara S, Weerawansa P, Matthias MA, Vinetz JM. Regional Differences of Leptospirosis in Sri Lanka: Observations from a Flood-Associated Outbreak in 2011. PLOS Neglected Tropical Diseases 2014, 8: e2626. PMID: 24454971, PMCID: PMC3894175, DOI: 10.1371/journal.pntd.0002626.Peer-Reviewed Original ResearchConceptsOutbreak of leptospirosisClinical presentationAcute renal failureDifferent clinical presentationsCross-sectional studyMedian bacterial loadPublic health interventionsPublic health relevanceLeptospira interrogans serovar laiRenal failureSevere thrombocytopeniaInfectious disease epidemicsDifferent Leptospira speciesEtiological causesImportant causeHealth interventionsHealth relevanceLeptospirosisTropical diseasesBacterial loadLeptospira kirschneriLeptospirosis outbreaksSerovar laiLeptospira speciesL. kirschneri
2009
Chapter 47 Transfusion of HIV-positive Patients
Hendrickson J, Roback J. Chapter 47 Transfusion of HIV-positive Patients. 2009, 275-278. DOI: 10.1016/b978-0-12-374432-6.00047-6.Peer-Reviewed Original ResearchHIV-positive patientsAcquired Immunodeficiency SyndromeHuman immunodeficiency virusMultiple hematologic abnormalitiesSevere symptomatic anemiaUnderlying HIV infectionTransfusion of RBCsPotential immunomodulatory roleTransfusion-transmitted virusesTreatment of anemiaHIV diseaseSymptomatic anemiaHIV infectionImmunodeficiency syndromePlatelet transfusionsSevere thrombocytopeniaImmunodeficiency virusImmunomodulatory roleHematologic abnormalitiesHematologic conditionsVitamin deficiencyIneffective hematopoiesisTransfusionPatientsAdvanced stage
2008
Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response
Kenney B, Tormey CA. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets 2008, 19: 379-383. PMID: 18791945, DOI: 10.1080/09537100802082280.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAmputation, SurgicalAnti-Bacterial AgentsAntigens, Human PlateletAutoantibodiesBacteremiaCeftazidimeDrug Therapy, CombinationFoot DiseasesGram-Positive Bacterial InfectionsHumansImmunoglobulin GImmunoglobulin MImmunologic MemoryMaleMiddle AgedPurpura, Thrombocytopenic, IdiopathicSurgical Wound InfectionVancomycinConceptsAntibiotic therapyPlatelet antibodiesPlatelet countPlatelet destructionAdverse bleeding eventsAnamnestic antibody responseDrug-related thrombocytopeniaNew onset thrombocytopeniaRapid platelet destructionAnti-platelet antibodiesNormal platelet countCases of thrombocytopeniaSafe drug useBleeding eventsVancomycin administrationWet gangreneImmune thrombocytopeniaImmediate discontinuationRare complicationMale patientsAnamnestic responseDrug withdrawalSevere thrombocytopeniaAcute reductionPrior sensitization
1996
Antenatal management of alloimmune thrombocytopenia with intravenous γ-globulin: A randomized trial of the addition of low-dose steroid to intravenous γ-globulin
Bussel J, Berkowitz R, Lynch L, Lesser M, Paidas M, Huang C, McFarland J. Antenatal management of alloimmune thrombocytopenia with intravenous γ-globulin: A randomized trial of the addition of low-dose steroid to intravenous γ-globulin. American Journal Of Obstetrics And Gynecology 1996, 174: 1414-1423. PMID: 9065105, DOI: 10.1016/s0002-9378(96)70582-3.Peer-Reviewed Original ResearchMeSH KeywordsCerebral HemorrhageDexamethasoneDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFetal BloodFetal DiseasesHumansImmunoglobulins, IntravenousIsoantibodiesMaternal-Fetal ExchangePlatelet CountPrednisonePregnancyProspective StudiesSalvage TherapyThrombocytopeniaTreatment OutcomeConceptsIntravenous γ-globulinAlloimmune thrombocytopeniaThrombocytopenic fetusesIntracranial hemorrhageIntravenous gamma globulin treatmentGamma globulin treatmentLow-dose steroidsUtero platelet transfusionsFetal blood samplingMaternal infusionAntenatal managementSevere thrombocytopeniaΓ-globulinPlatelet countPlatelet transfusionsBlood samplingFetal bloodThrombocytopeniaPlatelet increaseDexamethasoneFetusesGm/PrednisoneNonrespondersHemorrhage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply